Incidence of pediatric melanoma on the decline
the ONA take:
According to a new study published in the Journal of Pediatrics, researchers from Case Western University and University Hospitals in Cleveland, Ohio, have found that the incidence of pediatric melanoma in the United States has declined from 2004-2010 despite other studies indicating that the incidence has been increasing.
For the study, researchers used data from the Surveillance, Epidemiology and End Results (SEER) databases to identify new cases of melanoma in pediatric patients between 2000 and 2010. Results showed that there were a total of 1,185 new cases of pediatric melanoma during that 10-year period.
The researchers found that the number of new cases decreased by 12% each year from 2004 to 2010. During the 10-year period studied, researchers observed a 7% decrease per year for boys, and from 2003 to 2010, there was an 11% decrease per year for 15 to 19-year-olds.
The authors suggest that effective public health initiatives, a transition to more indoor activities, and improved parental awareness to protect children from sun damage may be factors for the reduction of pediatric melanoma cases.
Incidence of pediatric melanoma in the United States has declined from 2004-2010.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|